PATENT CLAIM ANALYSIS

Application Number: 16270231
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-05
Patent Classification: ["424", "136100"]

Abstract:
The invention concerns isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2, whereby the antibodies bind additional CCR3-binding chemokines. The invention further concerns use of these antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.

Claim (Index 39):
A pharmaceutical composition comprising the antibody of  claim 31 , and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 99.0
- Lexical Diversity: 1.31818
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15122241', '13146711', '08963656', '11216610', '10283028']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7179488781253268
- 35 USC 102 Novelty (BERT): 0.5797010227244414
- Combined Prediction Score: 0.7041240925852383
- Mean Citation Score: 363.717174
- Max Citation Score: 566.102
- Similarity Product: 350.25062969470025

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test